The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial: Curcumin Supplementation for NAFLD
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a global health problem. Although many aspects of NAFLD pathogenesis have been understood, there is a paucity of effective treatments to be used as the second line when lifestyle modification is insufficient. Curcumin, a natural polyphenol from turmeric, has been shown to be effective against development of hepatic steatosis and its progression to steatohepatitis, yet these beneficial effects have not been explored in clinical practice. The aim of this study is to investigate the effects of curcumin on hepatic fat content as well as biochemical and anthropometric features of patients with NAFLD. In this randomized double-blind placebo-controlled trial, patients with ultrasonographic evidence of NAFLD were randomly assigned to receive an amorphous dispersion curcumin formulation (500 mg/day equivalent to 70-mg curcumin) or matched placebo for a period of 8 weeks. Liver fat content (assessed through ultrasonography), glycemic and lipid profile, transaminase levels, and anthropometric indices were evaluated at baseline and at the end of follow-up period. The clinical trial protocol was registered under the Iranian Registry of Clinical Trials ID: IRCT2014110511763N18. Compared with placebo, curcumin was associated with a significant reduction in liver fat content (78.9% improvement in the curcumin vs 27.5% improvement in the placebo group). There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group. Curcumin was safe and well tolerated during the course of trial. Findings of the present proof-of-concept trial suggested improvement of different features of NAFLD after a short-term supplementation with curcumin. Copyright © 2016 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,803
Vernon, G., Baranova, A., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,074
Power and Sample Size Calculations for Studies Involving Linear Regression
Dupont, W. D., & Plummer, W. D. (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(98)00037-3 · Cited by 1,024
Adams, L. A., Sanderson, S., Lindor, K. D., & Angulo, P. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2004.09.012 · Cited by 911
Curcumin Extract for Prevention of Type 2 Diabetes
Chuengsamarn, S., Rattanamongkolgul, S., Luechapudiporn, R., Phisalaphong, C., & Jirawatnotai, S. (2012) · Diabetes Care · doi:10.2337/dc12-0116 · Cited by 635
Curcumin Inhibits Adipogenesis in 3T3-L1 Adipocytes and Angiogenesis and Obesity in C57/BL Mice
Ejaz, A., Wu, D., Kwan, P., & Meydani, M. (2009) · The Journal of Nutrition · doi:10.3945/jn.108.100966 · Cited by 585
Izzo, A. A., Hoon‐Kim, S., Radhakrishnan, R., & Williamson, E. M. (2016) · Phytotherapy Research · doi:10.1002/ptr.5591 · Cited by 532
Panahi, Y., Hosseini, M. S., Khalili, N., Naimi, E., Majeed, M., & Sahebkar, A. (2015) · Clinical Nutrition · doi:10.1016/j.clnu.2014.12.019 · Cited by 406
Self-citationFatty Infiltration of Liver in Hyperlipidemic Patients
Assy, N., Kaita, K., Mymin, D., Levy, C., Rosser, B., & Minuk, G. (2000) · Digestive Diseases and Sciences · doi:10.1023/a:1005661516165 · Cited by 360
Cited by
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
Roehlen, N., Crouchet, E., & Baumert, T. F. (2020) · Cells · doi:10.3390/cells9040875 · Cited by 1,237
Soleimani, V., Sahebkar, A., & Hosseinzadeh, H. (2018) · Phytotherapy Research · doi:10.1002/ptr.6054 · Cited by 579
Self-citationPhytosomal curcumin: A review of pharmacokinetic, experimental and clinical studies
Mirzaei, H., Shakeri, A., Rashidi, B., Jalili, A., Banikazemi, Z., & Sahebkar, A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.11.098 · Cited by 517
Self-citationCellular and molecular mechanisms of curcumin in prevention and treatment of disease
Patel, S. S., Acharya, A., Ray, R. S., Agrawal, R., Raghuwanshi, R., & Jain, P. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2018.1552244 · Cited by 511
The therapeutic potential of curcumin: A review of clinical trials
Salehi, B., Stojanović-Radić, Z., Matejić, J., Sharifi-Rad, M., Anil Kumar, N. V., Martins, N., & Sharifi-Rad, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.12.016 · Cited by 495
Metadata
- Authors
- Rahmani, S., Asgary, S., Askari, G., Keshvari, M., Hatamipour, M., Feizi, A., & Sahebkar, A.
- Venue
- Phytotherapy Research
- Publisher
- Wiley
- Published
- 2016-06-08
- Volume
- 30
- Issue
- 9
- Pages
- 1540-1548
- ISSN
- 0951-418X (ISSN-L)
- OpenAlex
- W2412935642
- Cited by
- 460
- References
- 51
- FWCI
- 21.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial: Curcumin Supplementation for NAFLD. https://app.cochat.ai/papers/10.1002/ptr.5659
- The paper
- Rahmani, S., Asgary, S., Askari, G., Keshvari, M., Hatamipour, M., Feizi, A., & Sahebkar, A. (2016). Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial: Curcumin Supplementation for NAFLD. Phytotherapy Research. https://doi.org/10.1002/ptr.5659
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.